The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

The annual meeting of the American Heart Association was held this year from Nov. 16 to 18 in Chicago, drawing attendees from around the world, includ ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

The proposed rule could give millions of Americans access to the new drugs; it will also put pressure on the incoming Trump administration.

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...

Novo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that ...

Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden proposed expanding ...

Shares of Novo Nordisk gained 1.3% following U.S. President Biden's proposal to expand Medicare and Medicaid coverage for ...

Novo Nordisk's shares rose due to President Joe Biden's proposal to expand Medicare and Medicaid coverage for anti-obesity ...

Thermo Fisher has launched a suite of expanded CRO and CDMO services under its own brand, Accelerator™ Drug Development, intended to serve biotechs and pharmas.

Upcoming data from a mid-stage study of Amgen's experimental weight-loss drug MariTide will shed light on how well it might ...